Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Archives of Gynecology and Obstetrics
Published in: Archives of Gynecology and Obstetrics 3/2017

01-03-2017 | Gynecologic Oncology

Prognostic value of MMP-2 for patients with ovarian epithelial carcinoma: a systematic review and meta-analysis

Authors: Honglei Jia, Qingyu Zhang, Fanxiao Liu, Dongsheng Zhou

Published in: Archives of Gynecology and Obstetrics | Issue 3/2017

Login to get access

Abstract

Background

The reported roles of matrix metalloproteinase 2 (MMP-2) on the prognosis of patients with epithelial ovarian cancers (EOCs) are inconsistent.

Objective

This meta-analysis was performed to evaluate the prognostic significance of MMP-2 for patients with EOCs by analyzing 11 studies.

Methods

We systematically searched articles in the Cochrane Library, Pubmed, Embase, China National Knowledge Infrastructure (CNKI), Wanfang Database, and Chinese Biological Medical (CBM) Database, updated to February 1st 2015, with the following search terms: ovarian neoplasm OR ovarian tumor OR ovarian carcinoma OR ovarian malignance OR ovarian cancer AND matrix metalloproteinase-2 OR MMP-2.

Results

A total of 11 studies involving 1058 patients with EOCs were in accordance with the inclusion criteria. The pooled HR was 1.09 (95% CI 0.32–1.86, p = 0.006) in patients with overexpression of stromal MMP-2 with significant heterogeneity (I 2 = 53.1%, p = 0.074) between studies. For patients with MMP-2 overexpression in tumor cells, the pooled HR was 1.42 (95% CI 1.14–1.70, p = 0.000) with no significant heterogeneity (I 2 = 43.4%, p = 0.078) between studies. Sensitivity analyses were stable.

Conclusions

MMP-2 overexpression in tumor cells rather than stroma was significantly associated with poor prognosis in patient with endothelial ovarian cancer; however, the result remains to be confirmed with additional high-quality studies.
Literature
1.
American Cancer Society (2015) Cancer facts and figures 2015. American Cancer Society, Atlanta
2.
Sun C, Li N, Ding D et al (2014) The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis. PLoS One 9:95285CrossRef
3.
Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108CrossRefPubMed
4.
Liu R, Lu S, Deng Y et al (2016) PSMB4 expression associates with epithelial ovarian cancer growth and poor prognosis. Arch Gynecol Obstet 293(6):1297–1307CrossRefPubMed
5.
Perigny M, Bairati I, Harvey I et al (2008) Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am J Clin Pathol 129:226–231CrossRefPubMed
6.
Sterne JA, Egger M (2001) Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54:1046–1055CrossRefPubMed
7.
Pan Y, Zhu D, Si WN et al (2008) Expressions of RhoC and MMP-2 proteins in epithelial ovarian cancer tissues and their clinical significances. J Jilin Univ Medicine Edition) 34:1042–1045
8.
Kucukgoz GU, Gumurdulu D, Guzel AB et al (2014) Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma. Arch Gynecol Obstet 289(2):393–398CrossRef
9.
Peng H, Liu L, Zhao X (2013) Prognostic significance of matrix metalloproteinase-2 in gynecological cancer: a systemic review of the literature and meta-analysis. J BUON 18:202–210PubMed
10.
Horner MJ, Ries LAG, Krapcho M et al (2009) SEER Cancer Statistics Review, 1975–2006, National Cancer Institute. In: Bethesda, MD (ed) SEER Cancer Statistics Review
11.
12.
Yu L, Wang WY, Gan HY et al (2011) Expression and clinical significance of MMP-2 and MMP-7 in ovarian carcinoma. Chinese J Histochem Cytochem 20:325–329
13.
Huang KJ, Sui LH (2012) The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer. Med Oncol 29:318–323CrossRefPubMed
14.
Liu J, Ping W, Zu Y et al (2014) Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer. Int J Clin Exp Pathol 7:6040–6047PubMedPubMedCentral
15.
Ekinci T, Ozbay PO, Yiğit S et al (2014) The correlation between immunohistochemical expression of MMP-2 and the prognosis of epithelial ovarian cancer. Ginekol Pol 85:121–130CrossRefPubMed
16.
Lynch CC (2011) Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis. Bone 48:44–53CrossRefPubMed
17.
Wen X, Liu H, Yu K et al (2014) Matrix metalloproteinase 2 expression and survival of patients with osteosarcoma: a meta-analysis. Tumour Biol 35:845–848CrossRefPubMed
18.
Su Z, Graybill WS, Zhu Y (2013) Detection and monitoring of ovarian cancer. Clin Chim Acta 415:341–345CrossRefPubMed
19.
Wu DB, Yang J, Yao YL et al (2013) Expression and clinical significance of MMP-2 and MMP-7 in ovarian carcinoma. Proceed Clin Med 22:650–652
20.
Wells G, Shea B, Peterson J et al (2000) The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 3rd symposium on systematic reviews: beyond the basics. pp 3–5
21.
Gentry-Maharaj A, Menon U (2012) Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol 26:243–256CrossRefPubMed
22.
23.
Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834CrossRefPubMed
24.
Wang XY, Zhang YK, Ren GH (2004) Relation between expression of MMP-2 and MMP-9 and invasion, metastasis of epithelial carcinoma of ovary. Chin J Oncol Rahabil 11:406–408
25.
Westerlund A, Apaja-Sarkkinen M, Höyhtyä M et al (1999) Gelatinase A-immunoreactive protein in ovarian lesions- prognostic value in epithelial ovarian cancer. Gynecol Oncol 75:91–98CrossRefPubMed
26.
Torng PL, Mao TL, Chan WY et al (2004) Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. Gynecol Oncol 92:559–567CrossRefPubMed
27.
Kamat AA, Fletcher M, Gruman LM et al (2006) The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res 12:1707–1714CrossRefPubMedPubMedCentral
28.
Sillanpaa S, Anttila M, Suhonen K et al (2007) Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer. Tumour Biol 28:280–289CrossRefPubMed
29.
Wu X, Li H, Kang L et al (2002) Activated matrix metalloproteinase-2–a potential marker of prognosis for epithelial ovarian cancer. Gynecol Oncol 84:126–134CrossRefPubMed
30.
Davidson B, Reich R, Berner A et al (2001) Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur J Cancer 37:2040–2049CrossRefPubMed
31.
Chen VW, Bernardo R, Jeffrey L et al (2003) Pathology and classification of ovarian tumors. Cancer 97(10 Suppl):2631–2642CrossRefPubMed
32.
Yu WH, Woessner JF Jr, McNeish JD et al (2002) CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 16:307–323CrossRefPubMedPubMedCentral
33.
Campo E, Merino MJ, Tavassoli FA et al (1992) Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol 16:500–507CrossRefPubMed
34.
Lydiksen L, Jensen-Fangel S, Blaakaer J (2014) Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer? Gynecol Oncol 133:454–459CrossRefPubMed
35.
Metadata
Title
Prognostic value of MMP-2 for patients with ovarian epithelial carcinoma: a systematic review and meta-analysis
Authors
Honglei Jia
Qingyu Zhang
Fanxiao Liu
Dongsheng Zhou
Publication date
01-03-2017
Publisher
Springer Berlin Heidelberg
Published in
Archives of Gynecology and Obstetrics / Issue 3/2017
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-016-4257-9

Other articles of this Issue 3/2017

Archives of Gynecology and Obstetrics 3/2017 Go to the issue

General Gynecology

Elevated RON protein expression in endometriosis and disease-associated ovarian cancers

Gynecologic Endocrinology and Reproductive Medicine

The effect of dexpanthenol on experimentally induced ovarian ischaemia/reperfusion injury: a biochemical and histopathological evaluation

Review

Usage of the levonorgestrel-releasing intrauterine system (LNG-IUS) in adolescence: what is the evidence so far?

General Gynecology

Current practice patterns for management of vulvodynia in the United States

Gynecologic Endocrinology and Reproductive Medicine

Prediction of fetal loss by first-trimester crown–rump length in IVF pregnancies

Gynecologic Oncology

Intraoperative nerve staining in nerve-sparing radical hysterectomy: a pilot study